CFD
ATNM icon

Creative Financial Designs’s Actinium Pharmaceuticals ATNM Stock Holding History

Creative Financial Designs’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-109,381
Closed -$153K – 2053
2025
Q2 		$153K Buy
109,381
+3,750
+4% +$5.61K 0.01% 558
2025
Q1 		$170K Buy
105,631
+14,624
+16% +$18.6K 0.01% 486
2024
Q4 		$115K Buy
91,007
+27,222
+43% +$42.2K 0.01% 567
2024
Q3 		$120K Buy
63,785
+41,250
+183% +$163K 0.01% 557
2024
Q2 		$167K Sell
22,535
-300
-1% -$2.47K 0.01% 470
2024
Q1 		$179K Buy
22,835
+3,035
+15% +$19.5K 0.02% 444
2023
Q4 		$101K Buy
19,800
+3,175
+19% +$16.4K 0.01% 536
2023
Q3 		$98.4K Buy
16,625
+150
+0.9% +$998 0.01% 494
2023
Q2 		$122K Buy
16,475
+1,475
+10% +$12.6K 0.01% 439
2023
Q1 		$142K Buy
+15,000
New +$158K 0.02% 396

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Creative Financial Designs's ATNM Position: Q3 2025 in Review

Creative Financial Designs sold out of Actinium Pharmaceuticals (ATNM) in Q3 2025, closing a stake of 109,381 shares — an estimated $153K sold.

Creative Financial Designs first reported a position in ATNM in Q1 2023 and held it in 10 quarters. The position peaked at $179K in Q1 2024. 61 funds tracked by Wall St. Rank hold ATNM as of Q3 2025.

  • Creative Financial Designs reported no remaining Actinium Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Creative Financial Designs sold 109,381 Actinium Pharmaceuticals shares in Q3 2025, an estimated $153K.
  • Creative Financial Designs first reported a position in Actinium Pharmaceuticals in Q1 2023 and held it in 10 quarters.
  • Creative Financial Designs's Actinium Pharmaceuticals position peaked at $179K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2025.

Based on Creative Financial Designs's 13F filing for Q3 2025, filed 12 Nov 2025.